longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Aardvark Therapeutics

AARD

5.2701.50% ( -0.080 )
Closed: Sep 30, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -1.65, within the reasonable range, cheaper than 21.84% of the time in the past 1 years, and the industry ranks 125/256, the industry Median -1.38.

-1.65xP/E
$5.27Stock price
$-3.19Earnings per share
-1.65xP/E
Stock price$5.27Earnings per share$-3.19

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-2.19x
Typical range
-6.15x–-1.62x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-55.04x149.86%$57.47B
BAYRYUSBayer
-26.29x--$53.05B
BAYZFUSBayer Aktiengesellschaft
-26.87x--$54.21B
VTRSUSViatris
-49.56x107.75%$20.35B
ELANUSElanco Animal Health
-56.21x129.36%$11.19B
AXSMUSAxsome Therap
-50.40x26.69%$9.66B
VREOFUSVIREO GROWTH INC
-136.72x--$9.18B
CURLFUSCuraleaf Holdings, Inc.
-150.95x--$7.85B
BLTEUSBelite Bio
-66.81x29.87%$6.84B
DFTXUSDefinium Therapeutics
-14.46x53.61%$5.11B
MANEUSVeraDermics
-48.57x97.44%$5.07B
EWTXUSEdgewise Therapeutics
-22.36x137.29%$4.41B
AMLXUSAmylyx Pharmaceuticals
-24.01x1.76%$3.65B
TARSUSTarsus Pharmaceuticals
-74.22x205.82%$3.45B
ELVNUSEnliven Therapeutics
-31.71x1.17%$3.36B
RGCUSRegencell Bioscience
-437.23x--$3.08B
MBXUSMBX Biosciences
-27.07x30.54%$2.82B
SUPNUSSupernus Pharma
-22.77x70.59%$2.50B
GPCRUSStructure Therapeutics
-10.38x102.05%$2.23B
PHVSUSPharvaris BV
-11.22x9.52%$2.23B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.